Your search returned 2 results.

Results
	1.	Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. MedStar authors: McCarron, Edward C PMID: 30509771 Year: 2019 Citation: Lancet Oncology. 20(1):88-99, 2019 01. Institution: MedStar Franklin Square Medical Center Medline publication type: Journal Article Form of publication: Journal Article All authors: Bandos H, Brufsky AM, Chia SK, Dakhil SR, Fehrenbacher L, Geyer CE Jr, Graham ML, Jeong JH, Lembersky BC, Mamounas EP, McCarron EC, Paik S, Rastogi P, Seay TE, Soori GS, Swain SM, Wade JL 3rd, Walshe JM, Wickerham DL, Wolmark N DOI: https://dx.doi.org/10.1016/S1470-2045(18)30621-1 Add to cart (remove)
	2.	Live birth associated with peak serum estradiol levels in letrozole intrauterine insemination cycles. MedStar authors: Devine, Kate Kodama, Samantha PMID: 36634734 Year: 2023 Citation: Fertility & Sterility. 119(5):785-791, 2023 05. Institution: MedStar Washington Hospital Center Department: Obstetrics & Gynecology Residency Obstetrics and Gynecology Medline publication type: Journal Article Form of publication: Journal Article All authors: New EP Kodama S Devine K Jahandideh S Imudia AN Plosker SM DOI: https://dx.doi.org/10.1016/j.fertnstert.2023.01.003 Add to cart (remove)

Refine your search